IN THE SPECIFICATION:

Please replace paragraph beginning at page 2, line 19 and ending at page 2, line 23 as following:

--One aspect of the present invention contemplates a composition comprising leukaemia inhibitory factor (LIF) or a derivative or homologue thereof and a stabilizing agent facilitating chemical and/or physical stability of LIF in the composition, and one or more pharmaceutically acceptable carries and/or diluents.--

Please delete the paragraphs beginning at Page 5, Line 10 and ending at Page 5, Line 25.

Please replace paragraph beginning at page 10, line 21 and ending at page 10, line 25 as following:

--The compositions of the present invention achieve their stability through judicious choice of pH conditions within the range of from about 3.5 to about 6.5 inclusive and optionally the presence of one or more suitable stabilizing agents. Preferably, the pH range is between from about 4.0 - 6.0 inclusive, more preferably between from about 4.5 to about 5.5 inclusive. Most preferably, the pH of the composition is about 5.0.--

Please replace paragraph beginning at page 11, line 33 and ending at page 12, line 7 as following:

--The carrier must be pharmaceutically "acceptable" in the sense of being compatible with the other ingredients of the composition and not injurious to the subject. The compositions may conventionally be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In

general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers of finely divided solid carriers or both, and then if necessary shaping the product.--

Please replace paragraph beginning at page 12, line 27 and ending at page 12, line 33 as following:

--Compositions suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidant, buffers, bactericides and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition to detect changes in chemical and physical degradation.--

Please replace paragraph beginning at page 14, line 11 and ending at page 14, line 15 as following:

--The inventors examined a number of pH levels and stabilizing agents. Samples at pH 4.0, 4.5, 5.0, 5.5 and 6.0 were prepared in Examples 1 and 2, as described hereinafter, and additional stabilizing agents, Sorbitol, an isotonicity agent, and Polysorbate 80 (also referred to as Tween-80), as a non-ionic surfactant to reduce non-specific adsorption into surfaces, including glass, were also included. NaCl was also examined as an isotonicity agent.--

Please replace paragraph of "I. Sample Preparation" on page 49 as following:

--I. Sample Preparation

8°C and 25°C LIF Samples

LIF formulations were prepared by a dilution of stock LIF (3.67 mg/ml in 2 mM phosphate buffer) with citrate buffer containing sorbitol or NaCl to give a final LIF concentration of 0.05 or 0.4 mg/ml, a final buffer concentration of 10 mM, a final sorbitol concentration of 5% w/v or a final NaCl concentration of 0.9% w/v. The theoretical pH was 5.0 in all cases. Formulations were prepared and filled into vials as described previously.--

Please replace first paragraph of "III. Results" as following:

--III. Results

Ion Exchange

IEC data for 0.4 mg/ml formulations are shown in Tables 20 and 21. The results expressed as a percentage of the initial concentration remaining after the storage period indicated that the most stable formulations were the pH 5.0 citrate buffer containing sorbitol and Tween 80 and the pH 5.0 citrate buffer containing NaCl. The least stable was the pH 5 citrate buffer containing only sorbitol and pH 5.5 citrate containing sorbitol and Tween 80 was somewhere in the middle. --

REMARKS

In the Official Action dated April 9, 2002, Claims 1-3, 6-18, 20-26, 28-30, 32, 34-35 are under consideration. The amendment filed January 11, 2002 has been objected to under 35 U.S.C. §132 as allegedly introducing new matter. The specification has been objected to as allegedly lacking page 4. Claim 6 has been rejected under 35 U.S.C. §112, second paragraph, as